跳至主要内容
临床试验/ChiCTR2500112638
ChiCTR2500112638尚未招募Unknown

A pilot, open-label case series on the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients

GenieBiome Limited1 个研究点 分布在 1 个国家开始时间: 2025年11月17日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
试验地点
1
主要终点
Prevention of Significant Hair Loss

研究概览

简要总结

  • To explore the efficacy and safety of a synbiotic formula (HQP08) in preventing and managing chemotherapy-induced alopecia in cancer patients
  • To study the compositional and functional changes in gut microbiome

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 60(—)
性别
All

入选标准

  • Individuals aged 18 - 60 who is newly diagnosed with stage I, II or III cancer
  • Planned chemotherapy to be completed within 6 months
  • Literate and can complete the self-report questionnaires
  • Able to understand the consent and sign the informed consent form

排除标准

  • Metastatic cancers with life expectancy <6 months
  • Pre-existing female-pattern or male-pattern baldness
  • History of hair transplantation, psoriasis or severe scalp infection
  • Undergoing or plan to receive scalp cooling
  • Plan for immunotherapy
  • Severe cardiac, hepatic, renal, pulmonary and haematic lesions or other life-threatening conditions
  • Known pregnancy or lactating
  • Use of antibiotics, probiotics or prebiotics in the last 4 weeks
  • History of allergy to probiotics or lactose
  • History of chemotherapy for other conditions

研究组 & 干预措施

病例组

对照组

结局指标

主要结局

Prevention of Significant Hair Loss

次要结局

  • Changes in self-reported hair loss severity
  • Changes in self-reported hair loss
  • Changes in hair loss severity
  • Changes in depression level
  • Changes in anxiety level
  • Changes in quality of life
  • Gut microbiota composition and functions
  • Reduction of chemotherapy-related adverse events
  • Adverse Events

研究者

研究点 (1)

Loading locations...

相似试验